Tasigna Capsule
Product Images NDC 0078-0526

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Tasigna (NDC 0078-0526). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Novartis Pharmaceuticals Corporation, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure Of Nilotinib (Tasigna 01)

Chemical structure of nilotinib hydrochloride monohydrate, the active ingredient in Tasigna capsules. The diagram depicts the molecular arrangement, including aromatic rings, nitrogen atoms, and functional groups characteristic of nilotinib.*

FDA Label Image

Figure 1: Kaplan-meier Estimate Of Treatment-free Survival After Start Of Tfr (full Analysis Set Enestfreedom) (Tasigna 02)

A Kaplan-Meier survival curve illustrating treatment-free survival percentage over time in weeks since treatment-free remission (TFR). The graph shows survival decreasing from 100% at week 0, with censored observations marked, and includes numbers of patients at risk and events occurring at specified intervals up to approximately 144 weeks.*

FDA Label Image

Figure 2: Kaplan-meier Estimate Of Treatment-free Survival After Start Of Tfr (full Analysis Set Enestop) (Tasigna 03)

A Kaplan-Meier survival curve chart depicting treatment-free survival percentage over time in weeks for a patient group. The graph includes censored observations marked along the curve and notes the number of patients at risk and events at various time points.*

FDA Label Image

Principal Display Panel Ndc 0078-0951-66 120 Capsules Rx Only Tasigna® (nilotinib) Capsules 50 mg Dispense With Medication Guide Novartis (Tasigna 06)

Tasigna 50 mg capsules packaging label showing the oral capsule dosage form containing 50 mg nilotinib. The label includes the total quantity of 120 capsules and instructions to take Tasigna on an empty stomach. The labeler is Novartis Pharmaceuticals Corporation, with storage instructions and distribution details visible.*

FDA Label Image

Principal Display Panel Ndc 0078-0592-87 Tasigna® (nilotinib) Capsules 150 mg Per Capsule Dispense With Medication Guide Attached Or Provided Separately. Novartis (Tasigna 04)

Tasigna 150 mg capsules packaging label shows the brand and generic names (nilotinib), dosage strength (150 mg), and dosage form (oral capsules). The label states it contains 4 individual blister packs of 28 capsules each. Manufactured by Novartis Pharma Stein AG, Switzerland, and distributed by Novartis Pharmaceuticals Corp., East Hanover, NJ. Storage and dosing precautions are noted, along with contact information for more details.*

FDA Label Image

Principal Display Panel Ndc 0078-0526-87 Tasigna® (nilotinib) Capsules 200 mg Per Capsule Dispense With Medication Guide Attached Or Provided Separately. Novartis (Tasigna 05)

Packaging label for Tasigna (nilotinib) capsules 200 mg by Novartis Pharmaceuticals Corporation. The carton contains 4 individual blister packs, each with 28 capsules. The label includes dosage instructions, storage conditions, manufacturer and distributor information, and a warning to take Tasigna on an empty stomach with specific timing.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.